A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer (eMonarcHER) Sign up for this study
- ID
- NCT04752332
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 111 people participating
- Last Updated